CLINICAL EXPERIENCE AND USE OF VIGABATRIN IN PATIENTS WITH INFANTILE SPASMS

婴儿痉挛症患者氨己烯酸的临床经验和使用

• 批准号: 6244814
• 负责人: WENDY G. MITCHELL
• 金额: $ 3.96万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-23 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244814
• 关键词: anticonvulsants; brain disorder chemotherapy; child (0-11); clinical research; drug screening /evaluation; epilepsy; generalized seizures; human subject; human therapy evaluation; infant human (0-1 year); spasm

Infantile spasms are a severe type of seizures which occur in infants. The outlook for a child with infantile spasms is poor: most are developmentally disabled, and a majority continue to have severe epilepsy. ACTH is the most commonly used treatment for infantile spasms and is successful at least temporarily in about 70%. However, adverse effects are significant. Conventional anticonvulsants are only occassionally effective. Vigabatrin, a new anticonvulsant is being evaluated for safety and efficacy in treating infantile spasms.

婴儿痉挛是一种严重的癫痫发作类型，发生在婴儿身上。 患有婴儿痉挛的儿童前景黯淡：大多数是 发育障碍，大多数人继续患有严重的 癫痫。促肾上腺皮质激素是治疗婴儿痉挛最常用的方法。 至少在70%左右是暂时成功的。然而，不利的是 影响是显著的。传统的抗惊厥药物只是 有时是有效的。一种新的抗惊厥药物Vigabatrin正在研制中 对治疗婴儿痉挛的安全性和有效性进行评估。